TITLE:
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

CONDITION:
Acute Myeloid Leukemia

INTERVENTION:
Gemtuzumab Ozogamicin

SUMMARY:

      The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab
      ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab
      ozogamicin when given concurrently with cytarabine.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Morphologic diagnosis of AML from bone marrow aspirate and biopsy

          -  Flow cytometry, performed at the study site, must demonstrate that the patient has
             AML that is CD33+, based on local laboratory criteria

          -  Age 18 years or older for relapsed or refractory patients for Phase I of this study

        Exclusion Criteria:

          -  Patients with de novo AML of the M3 subtype

          -  AML following an antecedent hematologic disorder (myelodysplasia or
             myeloproliferation) of > 2 months duration

          -  AML secondary to exposure to chemotherapy or radiation
      
